SiNtx TechnologiesSINT
Recorded

SiNtx Technologies 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration26 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, and welcome to SINTX Technologies Third Quarter 2026 Earnings Conference Call. All participants are in listen-only mode. As a reminder, today's call is being recorded. I would now like to turn the call over to SINTX Technologies Chief Legal Officer, Kevin Ontiveros.

Kevin OntiverosChief Legal Officer

Thank you, operator, and good afternoon, everyone. Earlier today, SINTX Technologies released its financial results for the quarter ended September 30, 2026, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. These materials, together with a replay of this call, will be available through the Investor Relations section of the SINTX Technologies website. Before we begin, I want to remind listeners that statements on today's call, other than historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about customer orders, production and shipment schedules, future revenue and guidance, gross margins, medical device commercialization, surgeon and distributor adoption, research and development, intellectual property, strategic relationships, potential financing and warrant exercises, liquidity, and business outlook. They reflect current expectations, involve risks and uncertainties, and actual results may differ materially.

Kevin OntiverosChief Legal Officer

Please review the risk factors and other disclosures in our latest Forms 10-K and 10-Q and subsequent SEC filings. SINTX undertakes no duty to update these statements except as required by law. Unless otherwise noted, financial measures discussed today are presented on a US GAAP basis. Joining me are Eric Olson, our Chairman and Chief Executive Officer, and Kevin Trask, our Chief Financial Officer. Eric will provide the business and strategic update, Kevin will review financial results and liquidity, and Eric will close with our near-term priorities. At this time, I would like to turn the call over to Eric Olson.

Eric OlsonChairman and CEO

Eric? Thank you, Kevin, and thank you to everyone for joining today's call.

Eric OlsonChairman and CEO

Our third quarter performance marks an important step in SINTX's transition into a commercially driven advanced biomaterials company. For many years, the strength of SINTX has been in silicon nitride technology, manufacturing expertise, and research and development capabilities. Today, we can announce that we have translated these strengths into sustainable commercial revenue and gross profits. I would like to highlight several third quarter takeaways. First, SINTX has manufactured and delivered more silicon nitride parts than in any other quarter in the company's history. Third quarter revenue grew 953%, reaching approximately $2.2 million compared with $208,000 a year earlier. This represents a meaningful step up in demonstrating commercial scale, driven primarily by our industrial and aerospace ceramics manufacturing operations. Second, gross profits reached approximately $1.4 million, while our net loss narrowed by 55% year over year.

Eric OlsonChairman and CEO

Third, achieving the Q3 revenue milestone allowed us to execute a warrant call, which resulted in gross capital proceeds of approximately $2 million, as well as the expiration of unexercised Class B warrants that would have covered the issuance of an additional 941,000 shares, reducing the dilution to existing shareholders. We anticipate the revenue from the industrial sales vertical will support us as we continue our transition to addressing unmet needs in medical devices and medical textiles, while also working to bring our cost structure more in line with our revenue.

Eric OlsonChairman and CEO

The update we will discuss today reinforces both our short and long-term business strategies focused on, first, industrial and aerospace revenue growth, second, commercialization of our FDA-cleared SiNAPTIC silicon nitride system for foot and ankle procedures, third, moving our silicon nitride PEEK 3D-printed orthopedic implants closer to commercialization, and fourth, the licensing of silicon nitride-treated medical textiles for wound closure and wound care applications. These strategies are possible thanks to our one-of-a-kind vertically integrated manufacturing facility, the only facility registered with the FDA to manufacture medical-grade silicon nitride biomaterials. This manufacturing capability, combined with our recent patents for integrating silicon nitride into composites and textiles, has allowed our platform to begin moving forward beyond traditional orthopedic devices and into other exciting biotech applications. As the only global manufacturer of medical-grade silicon nitride, we believe our priorities reflect a business that is not just about a single quarter's growth.

Eric OlsonChairman and CEO

It is about our ability to leverage a biomaterial platform to convert customer demand into delivered products and overall revenue growth. With that context in mind, I'd like to begin discussing our revenue growth in Q3 and what that means for the future of our silicon nitride business. Industrial manufacturing remained the primary contributor to third quarter revenue. Our experience in material formulation, precision manufacturing, and repeatable processing gives us an opportunity to deepen relationships with established industrial customers who need reliable components that perform in demanding environments. Purchase orders received this year from Fortune 500 aerospace companies informed the guidance we offered in our second quarter earnings call, where we indicated an expected revenue range of $900,000 to $1.1 million for the third quarter.

Eric OlsonChairman and CEO

Our ability to double the high end of these expectations is not only a testament of customer satisfaction, it is also a reflection of improvements in our manufacturing and operational efficiencies. Importantly, this execution demonstrated our capacity to manufacture at scale, which will become even more critical when applied to our medical device manufacturing throughput. As we discussed in our previous calls, receipt of these purchase orders represented the beginning of the work, not the completion of it. We indicated then that the important milestones included repeatable production, manufacturing yield, on-time delivery, and recognized revenue. We are pleased to report that we have demonstrated objective success in achieving these milestones and on an accelerated basis. Our ambition is to turn this success into a durable commercial foundation, that is, increasing capacity, obtaining repeat orders, and generating revenue that can support further development of our proprietary biomaterial platform.

Eric OlsonChairman and CEO

We are also expanding our dialogue with prospective manufacturing partners where our ceramic expertise can help solve specific technical challenges. The revenue from industrial sales provides an important source of growth and operational leverage as we expand our medical device and biomaterial platforms. To provide some quick background for listeners new to the SINTX story, the unique molecular properties of silicon nitride make it the ideal biomaterial for medical devices. Silicon nitride has several material characteristics that we believe make it attractive for medical device applications. These properties include being naturally antipathogenic and antimicrobial, which may decrease the likelihood of revision surgery during or due to infection, and osteoconduction, or the ability to stimulate bone growth, which could accelerate natural healing and help to prevent implant failures in the future. Implant-associated infections cost the U.S. healthcare system approximately $3 billion-$5 billion every year.

Eric OlsonChairman and CEO

Once bacteria adhere to implants made of other materials, such as metal or plastic, the bacteria becomes more resistant to antibiotics. Silicon nitride, on the other hand, has been shown to not only inhibit bacterial attachment in the first place, but to actually kill the bacteria as well. Published studies regarding silicon nitride have shown that these features may help to accelerate patient healing while also being less likely to cause allergic reactions and also provide more clear radiographic visibility than any other material, allowing for precise placement of implants in critical anatomic locations. Our lead proprietary silicon nitride product in this vertical remains the FDA 510(k)-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System. This implant system entered clinical use in the United States earlier this year, and we have begun the process of building a commercial channel around it.

Eric OlsonChairman and CEO

As you may recall, the SiNAPTIC system consists of silicon nitride wedges, which are being used in reconstructive procedures, including those to correct mid and hindfoot pathologies, and potentially for sports medicine applications as well. Following the completion of our limited use release that we have discussed in our previous call, full commercialization has now begun with distributors targeting the leading foot and ankle surgeons in the United States, while we also explore other strategic opportunities with partners that have existing relationships with facilities and foot and ankle surgeons. Commercial success of the system will be measured through surgeon adoption, product availability, repeat procedures or stickiness, and meaningful revenue. We are also evaluating capital-efficient routes to market, and we intend to build effective distribution and clinical support models while maintaining manufacturing and quality discipline.

Eric OlsonChairman and CEO

Beyond monolithic silicon nitride implants, our technology initiatives are intended to extend silicon nitride into new material formats and applications, including polymer composites and 3D manufacturing. We are pursuing commercialization strategies for patient-specific and custom implants, and we are entering into collaboration with partners who have the design, regulatory, and distribution capabilities needed to bring advanced products to market. We also continue to assess applications involving medical textiles, wound care, wound management, and other potential antipathogenic applications. 3D printing of orthopedic implants allow us to distribute a vast array of AI-assisted custom and patient-specific implants with complex geometries and patient-specific designs that may be difficult to achieve using traditional manufacturing methods. We believe these capabilities create new opportunities for our silicon nitride PEEK biocomposite platform. Last year, we announced a manufacturing agreement with Evonik, a leading global manufacturer of PEEK and PEEK-based filaments for 3D printing applications.

Eric OlsonChairman and CEO

Operating under our patent and using silicon nitride material provided by SINTX, Evonik produces a commercial-scale composite filament of PEEK and silicon nitride for these 3D-printed devices. Our patented silicon nitride PEEK biocomposite, which will be marketed as part of our, quote, "SiNERGY" biocomposite platform, combines the characteristics of these two materials and may offer advantages for certain orthopedic applications. We anticipate that 3D printing using the filament provided by Evonik may result in greater manufacturing yields, lower cost of goods, and less waste material than other manufacturing processes. Already, SINTX manufacturing and innovation teams have created a new 3D printing manufacturing facility and have also begun developing the custom workflows for these 3D-printed implant applications.

Eric OlsonChairman and CEO

SINTX is also currently conducting large animal in vivo studies to evaluate the effectiveness of medical textiles treated with silicon nitride and to advance preclinical work evaluating the antimicrobial and anti-adhesion scar reduction properties of silicon nitride-treated sutures and wound dressings for various wound healing and wound management applications. We anticipate that these studies will be completed in the next calendar quarter. These large animal studies are intended to help generate data regarding the healing performance of these materials in relevant wound environments and to inform future development and potential commercial partnering activities. We believe this represents a promising opportunity to extend our silicon nitride technology platform beyond traditional orthopedic implants. Ongoing testing and applicable regulatory clearances or approvals will be required before the commercialization or licensing of any resulting medical devices.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day